Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Novavax Rose 31% Last Month

By Jason Hawthorne - May 4, 2021 at 8:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Showered with optimism in April, shareholders will have to wait for the bloom.

What happened?

Novavax (NVAX 12.49%) had a busy month in April. Shares gained 30% according to S&P Global Market Intelligence. Early in the month, the stock began climbing after Johnson & Johnson's vaccine was temporarily halted. Later, President Joe Biden mentioned the company's vaccine as a likely tool in fighting the pandemic. Finally, cases around the world continue to climb, leading investors to believe there will be plenty of people who still need protection once the Novavax vaccine is available.

A woman with a COVID mask and bandaid after getting her vaccine.

Image source: Getty Images.

So what 

Investors translated the struggles of other vaccine makers into an opportunity for Novavax. That's despite the fact that the company's drug hasn't received authorization in any country. Nor has the company released the results from its Phase 3 trial in the U.S. and Mexico. That study began in December.

There is reason for optimism. Novavax has produced results from a study in the U.K that were on par with the vaccines that have been authorized.

Management had originally pointed to May as a possible date for authorization, which would tie in to Biden's suggestion. However, the first day of May brought news suggesting otherwise. 

What now?

Unfortunately for shareholders, Novavax gave back most of April's gains on the first trading day of May. The stock fell 18% after the company finalized a deal with the European Union for 200 million doses of its vaccine. That may seem like good news, but Wall Street spotted a problem: The bulk of those shots won't be delivered until 2022. 

For now, shareholders will continue to wait for authorization. Material shortages have hampered the company's efforts to reach full-scale production, and full capacity is now expected by the third quarter. That means Novavax's first shipments to Europe may begin toward the end of the year.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$64.29 (12.49%) $7.14
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.14 (-0.77%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.